slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 204,181-204,210
Pages 10,126
Rows per page 30
Component
204,181-204,210 of 303,780
02
Genprex | Investor Presentation Deck | 39 slidesGenprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style visualization to show the progress of different drug candidates.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
08
Uses a biological analogy (brake pedal) to explain gene function.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The slide uses a process flow diagram to explain the therapeutic mechanism of action.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Solution1 hit
11
The slide uses a 2x2 matrix structure to compare two patients across two time points.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Solution1 hit
15
Data presented at AACR 2021. Shows two separate mouse model experiments (H1975-OsiR and H1975).Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
16
The slide outlines a two-phase clinical trial structure and the specific patient progression timeline being measured.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
17
The slide outlines the clinical trial methodology for a drug combination study.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
21
The slide outlines a clinical trial methodology for a Phase 1/2 study.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
22
Clinical trial design summary for REQORSA combination therapy.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
23
The slide uses a histology image to visually demonstrate negative TUSC2 expression in SCLC.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
25
Genprex | Investor Presentation Deck | 39 slidesGenprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
27
The slide uses a two-column layout to contrast disease burden metrics with market size projections.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
11
The slide uses fluorescence microscopy images to demonstrate the mechanism of action (TUSC2 protein expression).Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
15
The slide presents two line charts comparing tumor volume over time across different treatment groups. It includes statistical significance markers (p-values) for the combination therapies.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
16
The slide outlines a clinical trial methodology comparing combination therapy against monotherapy continuation.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
17
Clinical trial methodology slide detailing study arms and endpoints.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
20
The slide uses TUSC2 as the synonym for REQORSA in the charts. Data shows statistical significance (p-values) for the triple combination.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
22
Clinical trial methodology slide detailing study design and endpoints for two phases.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
23
Includes a histological image showing negative TUSC2 expression.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
25
Genprex | Investor Presentation Deck | 44 slidesGenprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
27
The slide uses a two-column layout to contrast disease burden (left) with market size (right).Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
28
Genprex | Investor Presentation Deck | 44 slidesGenprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
The slide presents a Glucose Tolerance Test line chart and a bar chart for beta cell mass, demonstrating the efficacy of the AAV8-PM gene therapy.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
32
Includes a line chart showing blood glucose over time and a bar chart showing beta cell mass comparison.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
33
The charts track insulin/carb ratios over time relative to a viral infusion event.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
34
Includes a microscopic image of cells.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
35
Genprex | Investor Presentation Deck | 44 slidesGenprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
41
Genprex | Investor Presentation Deck | 44 slidesGenprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Action1 hit
42
The slide uses a two-column layout to contrast past progress with future goals.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Action1 hit